A randomized, double-blindphase 3 study of vadastuximab talirine (SGN-CD33A)versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2017
This article has no abstract
Epistemonikos ID: e0788617d96fd3c79924a4b1193084c64e6683d5
First added on: Apr 16, 2025